Monk, B., Concin, N., Richardson, D., Ray-Coquard, I., Pothuri, B., Marth, C., . . . Mirza, M. (2022). Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319). Gynecologic oncology, 166, S166. https://doi.org/10.1016/S0090-8258(22)01541-4
Citácia podle Chicago (17th ed.)Monk, Bradley, et al. "Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): A Posthoc Analysis of a Phase 1b Expansion Study in Ovarian Cancer (319)." Gynecologic Oncology 166 (2022): S166. https://doi.org/10.1016/S0090-8258(22)01541-4.
Citácia podľa MLA (8th ed.)Monk, Bradley, et al. "Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): A Posthoc Analysis of a Phase 1b Expansion Study in Ovarian Cancer (319)." Gynecologic Oncology, vol. 166, 2022, p. S166, https://doi.org/10.1016/S0090-8258(22)01541-4.